Table 13.2Line preservation according to infecting microorganism

Gram positive bacteriaStudies from 1980sStudies from 2000-
Staphylococcus aureus3/4 (75%) Hartman (1987)
21/25 (84%) De Pauw (1990)
4/6 (66.67%) Viscoli (1988)		1/3 (33.33%) Junqueira (2010)
3/3 (100%) Nosari (2008)
3/6 (50%) Joo (2011)
23/30 (76.67%) Park (2010)
Methicillin resistant staphylococcus aureus-5/12 (41.67%) Park (2010)
Coagulase negative staphylococcus-13/18 (72.22%) Joo (2011)
4/11 (36.36%) Junqueira (2010)
Staphylococcus epidermidis68/81 (83.95%) De Pauw (1990)
7/7 (100%) Viscoli (1988)
8/8 (100%) Hartman (1987)		17/22 (77.27%) Nosari (2008)
Enterococcus species5/7 (71.43%) De Pauw (1990)
0/1 (0%) Viscoli (1988)
2/3 (66.67%) Hartman (1987)		4/5 (80%) Nosari (2008)
Streptococcus5/5 (100%) Hartman (1987)
9/10 (90%) De Pauw (1990)
3/4 (75%) Viscoli (1988)		6/6 (100%) Junqueira (2010)
7/7 (100%) Nosari (2008)
Gram negative bacteriaStudies from 1980sStudies from 2000-
Pseudomonas aerguinosa4/5 (80%) Hartman (1987)
1/2 (50%) Viscoli (1988)		0/3 (0%) Joo (2011)
4/4 (100%) Nosari (2008)
Enterobacter species2/2 (100%) Hartman (1987)
1/1 (100%) Viscoli (1988)		3/4 (75%) Nosari (2008)
1/1 (100%) Joo (2011)
Escherichia coli2/3 (66.67%) Hartman (1987)0/2 (0%) Joo (2011)
8/9 (88.89%) Nosari (2008)
Klebsiella species2/2 (100%) Hartman (1987)1/1 (100%) Nosari (2008)
1/1 (100%) Joo (2011)
FungiStudies from 1980sStudies from 2000-
Candida albicans2/2(100%) Hartman (1987)
1/2(50%) Viscoli (1988)		-
Candida tropicalis2/2(100%) Hartman (1987)-
Any fungus-0/6(0%) Ruggiero (2010)

From: Initial Treatment: guideline chapter six

Cover of Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
NICE Clinical Guidelines, No. 151.
National Collaborating Centre for Cancer (UK).
Copyright © National Collaborating Centre for Cancer, 2012.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.